Resultats de la cerca - Alessandra Curioni‐Fontecedro

Refinar resultats
  1. 1
    A new era of oncology through artificial intelligence

    A new era of oncology through artificial intelligence per Alessandra Curioni‐Fontecedro

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere

    How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere per Giuseppe Luigi Banna, Alessandra Curioni‐Fontecedro, Alex Friedlaender, Alfredo Addeo

    Publicat 2019
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  3. 3
    Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer

    Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer per Christian Britschgi, Oliver Riesterer, Irene A. Burger, Matthias Gückenberger, Alessandra Curioni‐Fontecedro

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Genomic landscape of pleural and peritoneal mesothelioma tumours

    Genomic landscape of pleural and peritoneal mesothelioma tumours per Stefanie Hiltbrunner, Zoë Fleischmann, Ethan Sokol, Martin Zoche, Emanuela Felley‐Bosco, Alessandra Curioni‐Fontecedro

    Publicat 2022
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Frequent PD-L1 expression in testicular germ cell tumors

    Frequent PD-L1 expression in testicular germ cell tumors per Christian D. Fankhauser, Alessandra Curioni‐Fontecedro, V Allmann, J. Beyer, Verena Tischler, Tullio Sulser, Holger Moch, Peter Bode

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Mutant HRAS as novel target for MEK and mTOR inhibitors

    Mutant HRAS as novel target for MEK and mTOR inhibitors per Michael K. Kießling, Alessandra Curioni‐Fontecedro, Panagiotis Samaras, Kirstin Atrott, Jesús Cosín‐Roger, Silvia Lang, Michael Scharl, Gerhard Rogler

    Publicat 2015
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    <i>STRN</i><i>-ALK</i> Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment

    <i>STRN</i><i>-ALK</i> Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment per Jan H. Rüschoff, Elise Gradhand, Abdullah Kahraman, Helen Rees, Jane Ferguson, Alessandra Curioni‐Fontecedro, Martin Zoche, Holger Moch, Bart Vrugt

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Particle size and activation threshold: a new dimension of danger signaling

    Particle size and activation threshold: a new dimension of danger signaling per Lorna Rettig, Sebastian P. Haen, Anne Greet Bittermann, Lotta von Boehmer, Alessandra Curioni‐Fontecedro, Stefanie D. Krämer, Alexander Knuth, Steve Pascolo

    Publicat 2010
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    <sup>18</sup>F-FDG PET/CT of Non–Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response

    <sup>18</sup>F-FDG PET/CT of Non–Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathol... per Irene A. Burger, Ruben Casanova, Seraina Steiger, Lars Husmann, Paul Stolzmann, Martin W. Huellner, Alessandra Curioni‐Fontecedro, Sven Hillinger, C. Ross Schmidtlein, Alex Soltermann

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma

    Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma per Stefanie Hiltbrunner, Laura Mannarino, Michaela B. Kirschner, Isabelle Opitz, Angelica Rigutto, Alexander Laure, Michela Lia, Paolo Nozza, Antonio Maconi, Sergio Marchini, Maurizio D’Incalci, Alessandra Curioni‐Fontecedro, Federica Grosso

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  11. 11
    A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells

    A phase I clinical trial of malignant pleural mesothelioma treated with locally delivered autologous anti-FAP-targeted CAR T-cells per Alessandra Curioni‐Fontecedro, Christian Britschgi, Stefanie Hiltbrunner, Lorenz Bankel, P. Gulati, Walter Weder, Isabelle Opitz, Olivia Lauk, Claudio Caviezel, Alexander Knuth, Christian Münz, C. Renner, Rolf A. Stahel, Ulf Petrausch

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

    Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib per Joshua Bauml, Bob T. Li, Vamsidhar Velcheti, Ramaswamy Govindan, Alessandra Curioni‐Fontecedro, Christophe Dooms, Toshiaki Takahashi, Andrew W. Duda, Justin I. Odegaard, Fernando Cruz‐Guilloty, Liming Jin, Ying Zhang, Abraham Anderson, Ferdinandos Skoulidis

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program

    Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program per Solange Peters, Alessandra Curioni‐Fontecedro, Hovav Nechushtan, Jin‐Yuan Shih, Wei‐Yu Liao, Oliver Gautschi, Vito Spataro, Mojca Unk, James Chih‐Hsin Yang, Robert M. Lorence, Philippe Carrière, A. Cseh, Gee‐Chen Chang

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    [18F]FDG uptake of axillary lymph nodes after COVID-19 vaccination in oncological PET/CT: frequency, intensity, and potential clinical impact

    [18F]FDG uptake of axillary lymph nodes after COVID-19 vaccination in oncological PET/CT: frequency, intensity, and potential clinical impact per Stephan Skawran, Antonio Giulio Gennari, Manuel Dittli, Valérie Treyer, Urs J. Muehlematter, Alexander Maurer, Irene A. Burger, Cäcilia Mader, Olivia Messerli, Hannes Grünig, Cathérine Gebhard, Martin W. Huellner, Alessandra Curioni‐Fontecedro, Christoph Berger, Michael Messerli

    Publicat 2021
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype

    Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype per Stefanie Hiltbrunner, Lena Cords, Sabrina Kasser, Sandra N. Freiberger, Susanne Kreutzer, Nora C. Toussaint, Linda Grob, Isabelle Opitz, Michael Messerli, Martin Zoche, Alex Soltermann, Markus Rechsteiner, Maries van den Broek, Bernd Bodenmiller, Alessandra Curioni‐Fontecedro

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma

    Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma per Karīna Siliņa, Alex Soltermann, Farkhondeh Movahedian Attar, Ruben Casanova, Zina M. Uckeley, Helen Thut, Muriel Wandres, Sergejs Isajevs, Phil F. Cheng, Alessandra Curioni‐Fontecedro, Periklis Foukas, Mitchell P. Levesque, Holger Moch, Aija Linē, Maries van den Broek

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

    Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients per Paulino Tallón de Lara, Virginia Cecconi, Stefanie Hiltbrunner, Hideo Yagita∥, Martina Friess, Beata Bode, Isabelle Opitz, Bart Vrugt, Walter Weder, Paul Stolzmann, Emanuela Felley‐Bosco, Rolf A. Stahel, Verena Tischler, Christian Britschgi, Davide Soldini, Maries van den Broek, Alessandra Curioni‐Fontecedro

    Publicat 2018
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial

    Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial per Stefanie Hiltbrunner, Christian Britschgi, Petra Schuberth, Lorenz Bankel, Thi Dan Linh Nguyen‐Kim, P. Gulati, Walter Weder, Isabelle Opitz, Olivia Lauk, Claudio Caviezel, Hans Bachmann, Annett Tabor, Petra Schröder, Alexander Knuth, Christian Münz, Rolf A. Stahel, Onur Boyman, Christoph Renner, Ulf Petrausch, Alessandra Curioni‐Fontecedro

    Publicat 2020
    Obtenir text complet
    Carta
    Afegir a favorits
    Guardat en:
  19. 19
    A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

    A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from t... per Sanjay Popat, Alessandra Curioni‐Fontecedro, Varvara Polydoropoulou, Riyaz Shah, Mary O’Brien, A. Pope, P.M. Fisher, James Spicer, A. Roy, D. Gilligan, Oliver Gautschi, Ernest Nadal, Wolf-Dieter Janthur, Rafael López Castro, Rosario García Campelo, Heidi Roschitzki‐Voser, Barbara Ruepp, Sylvie Rusakiewicz, Solange Peters, Rolf A. Stahel

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

    A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Onc... per Sanjay Popat, Alessandra Curioni‐Fontecedro, Urania Dafni, R. Shah, Mary O’Brien, A. Pope, P.M. Fisher, James Spicer, A. Roy, D. Gilligan, Oliver Gautschi, Ernest Nadal, Wolf-Dieter Janthur, Rafael López Castro, Rosario García Campelo, Sylvie Rusakiewicz, Igor Letovanec, Varvara Polydoropoulou, Heidi Roschitzki‐Voser, Barbara Ruepp, A. Gasca-Ruchti, Solange Peters, Rolf A. Stahel

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: